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Uncontrolled excessive bleeding in daily life, whether due to sudden 
accident, surgical operations, or combat may cause infectious 
complications that may lead to death by shock. Therefore, topical 
hemostats and sealants are required to assist effective treatment, arrest 
bleeding, and stabilize the casualty before definitive care. 
This study use collagen and chitosan, which are both natural materials 
and are one of the most widely used hemostats these days. The materials 
are role in platelet activation, adhesion and aggregation. The use of 
chitosan helps the blood coagulation as it combines with red blood cells. 
However, these materials have been reported to lack sufficient hemostatic 
effect in a timely manner. 
Hence, in this research, a novel pad made a faster and more effective 
sponge type hemostats by using the recombinant batroxobin, a venomous 
component from the snake Bothrops atrox moojeni, which transforms the 
2 
 
fibrinogen to fibrin in the process of hemostasis; it expected that 
recombinant batroxobin would support natural substances to achieve a 
synergetic effect of hemostasis performances. First, collagen and 
chitosan were dissolved with batroxobin in acetic acid for fabrication of a 
novel hemostatic pad and then characteristic analysis using Scanning 
Electron Microscope. Fabricated sponge groups were collagen-only, 
chitosan-only, collagen with chitosan, collagen or chitosan containing 
recombinant batroxobin 1, 2 and 3 BU/well for in vitro studies, collagen 
or chitosan containing recombinant batroxobin 3 and 5 BU/well for in 
vivo studies and collagen with chitosan containing recombinant 
batroxobin 1, 2, 3 and 5 BU/well. Fibrinogen assay and platelet 
activation assays represented respective hemostats mechanism, even 
combination of the materials. Whole blood clotting assay and animal 
experiments investigated blood coagulation activities in the injury sites. 
In addition, H&E and PTAH staining methods for histological analysis. 
Through the experimentations result, a novel hemostatic pad confirmed 
that the substances maintained to their hemostatic properties in the pad, 
also coagulation studies proved pad effectively reduced blood loss and 
shortened bleeding time by addition of batroxobin.  
In conclusion, the novel hemostatic pad is reasonable that an enormous 
potential for excessive bleeding injury and improve effects of natural 
substance hemostatic pad when it is cooperated with recombinant 
batroxobin. 
 
 
 
---------------------------------------------------------------------------------------------------------- 
Key words : hemostasis, hemostatic pad, collagen, chitosan, recombinant batroxobin 
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I. INTRODUCTION 
 
1. Hemostasis 
Excessive hemorrhage occurs from serious accidents, preoperative 
measures for injury, and in warfare.
1,2
 Hemostasis can be divided into 
primary and secondary procedures as followed Figure 1. In primary 
hemostasis, extrinsic pathway, through tissue damage, can activate tissue 
factor (TF) and then TF and factor VII (tissue factor complex) may directly 
lead to generation of factor X. Along with extrinsic pathway, intrinsic 
pathway occurs by Hageman factor (factor XII) activation in the primary 
hemostasis process. Subsequently, platelet factor (PF-3) and clotting factor 
(factors VIII and IX) are precursor forms of cofactors for factor IX activation. 
Activated factor XII may directly initiate blood coagulation with factor VII.
3-6
 
Finally, secondary hemostasis, in other words blood coagulation cascade, is 
generated by factor X. The activation of factor X is catalyzed by factors IXa 
and VIIa. In blood coagulation cascade, factor X induces the production of 
prothrombinase. Prothrombinase triggers conversion of prothrombin to 
4 
 
thrombin. Fibrinogen transformation to fibrin occurs by means of generated 
thrombin. The created fibrin assists blood clotting, in addition to generating 
platelets through the primary process; activation and adhesion also help to 
make a hemostatic plug in conjunction with them.
6,7
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Figure 1. The process of hemostasis. Following damage to the blood vessel 
wall and tissue factor (TF) come into the contact with coagulation factors in the 
blood. TF in complex with factor VIIa and factor XII in complex with factor 
IXa activates minute amounts of factor X. Factor X activates prothrombin into 
thrombin which activates platelets. Additional Thrombin converts fibrinogen to  
monomeric fibrin that polymerizes to fibrin fibers.  
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2. Natural substances as hemostatic agents 
Among the many natural substances, this study focused on collagen and 
chitosan use for hemostatic efficacy. Generally, they are widely used as 
biomaterials, preoperative products, and for wound healing. Recent research 
has identified the substances as a promising hemostatic agent due to their 
potential bioactivity in hemostasis. 
First, collagen is the main component of the extracellular matrix, which is 
the triple helix protein structure. The collagen enables platelet aggregation 
and release of hemostatic factor for promoting coagulation and granulation 
tissue after blood coagulation.
8-10
 Moreover, collagen, and thereby the 
adherent platelets, assists in the formation of blebs with strong procoagulant 
activity; it is also extensively used in medical applications because of its low 
hazard of disease transmission.
9,11-13
 
Chitosan has been found to promote tissue growth and antimicrobial 
effects to advance wound healing. Chitosan is also an invaluable substance in 
biomaterials as a sealant for wound puncture sites, wound care, and drug 
delivery.
2,14-17
 In hemostasis, chitosan accelerates coagulation by activation 
and aggregation of platelets; it also involves the aggregation of 
erythrocyte.
18-20
 On the other hand chitosan nonspecific binding to cell 
membranes for assist of rapid hemostasis.
20
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3. Batroxobin 
Snake venoms consist of various components that have efficacy as 
coagulation agents. Generally, the components serve functions as fibrinogen 
clot enzyme, plasminogen activator, prothrombin activator, factor X activator, 
and hemorrhagins.
21-24
 One of the components, natural batroxobin, from the 
snake Bothrops atrox moojeni, acts as a thrombin-like enzyme in coagulation 
cascade. As shown in Figure 2, cleavage and removal of fibrinopeptides A (α 
chain) and B (β chain) from fibrinogen are catalyzed by thrombin. The 
cleaved fibrinopeptides polymerize, forming a fibrin polymer that is the main 
functional element of the hemostatic plug.
25,26
 The cleaved fibrinogen α chain 
initiates non-covalent combination to form fibrin clot.
27,28
 In contrast to 
thrombin, batroxobin only splits off fibrinopeptide A and does not affect 
polymerization for crosslinking networks of fibrin.
21,29
 In addition, batroxobin 
does not influence other hemostatic factor and cells. Because of this property, 
batroxobin can be used clinically as a stable hemostatic agent.
28
 Even though 
natural batroxobin has positive properties, it hard to use in commercialized 
product because of its high cost and short supply. For that reason, 
recombinant batroxobin was used for this study, from its cDNA expressed in 
Pichia pastoris. The recombinant batroxobin is more cost effective and can be 
mass produced. In addition, the recombinant batroxobin can used in acidic 
environments because it is not sensitive to pH level. 
 
 
 
 
  
 
 
 
8 
 
 
Figure 2. Schematic structure domains of fibrinogen and fibrin. fibrinogen 
convert fibrin to associate with D and E domains. D domain combines 
non-covalently with the specific binding site in the E domain. α and β chain is 
participate in fibrin polymerization through binding interactions. 
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4. Hemostatic pad 
When uncontrolled bleeding occurs due to complicated situations, 
advanced topical hemostatic agents are utilized to control hemorrhage. For 
that reason, many types of hemostatic agent have been used for effective 
control of excessive bleeding such as bandage, fibrin glue, liquid, powder, gel, 
and pad. One of the hemostats types is the pad (also referred to as scaffold), 
that can not only assist with effective control of bleeding but also stop oozing 
after the hemostasis process. In addition, the pad type covers the injury site to 
inhibit infection complications. Therefore, in this study, pads made by 
accreted materials in different mechanisms are used for more rapid and 
effective control of hemostasis. The three of mechanisms are role in 
hemostasis as described Figure 3. 
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Figure 3. The three of hemostatic agent mechanism in coagulation. Collagen is 
role of platelet adhesion and activation in hemostasis, also chitosan is role in 
hemostasis like collagen. In addition, chitosan is aggregation with erythrocyte 
for blood clot. Batroxobin assist of fibrinogen convert to fibrin as thrombin.  
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5. Objective of the study 
The present study sought to fabricate a novel hemostatic pad based on 
collagen and chitosan containing recombinant batroxobin. Batroxobin was 
expected to assist collagen and chitosan for a synergetic effect on rapid 
hemostasis. The mechanisms of respective components were evaluated by 
fibrinogen assay and platelet activation assay. A whole blood clot assay 
confirmed the blood clot ability and effect of batroxobin. Furthermore, 
animal model experiments provided a basis for confirming the efficacy of the 
novel pad. 
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II. MATERIALS AND METHODS 
 
1. Materials 
Bovine collagen type I fiber and Chitosan powder from shrimp shell (low 
viscosity) was purchased from Sigma-Aldrich Corporation (St. Louis, MO, 
USA). Recombinant batroxobin (r-Batroxobin) solution (recombinant 
batroxobin unit (BU/ml)) dissolved in phosphate buffered saline (PBS) was 
kindly donated by Biobud (Soengnam-si, Korea). Cyanmethemoglobin 
Standard Solution (Stanbio Laboratory, Boerne, TX, USA), equivalent to 180 
mg/ml of hemoglobin, was diluted in prepared Drabkin’s reagent for 
determinate concentrations of hemoglobin. All other reagent used were 
purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA). Grade 1 
filter paper (4.25 cm in diameter), purchased from Whatman (Kent, UK), was 
used for animal experiments. 4 mm biopsy punch purchased from Jeungdo 
bio&plant (Seoul, Korea). 
 
2. Fabrication of hemostatic pad 
A 1 % (w/v) collagen or chitosan powder was dissolved in 0.5 M acetic 
acid, pH 5.5. In addition, a blend of collagen and chitosan was prepared by 
through mixing of collagen and chitosan in 0.5 M acetic acid in the ratio of 
1:1. The solutions were then stirred at 4°C for 24 hr to obtain a homogenous 
solution. r-Batroxobin solution was added to each at the 23rd hour of mixing, 
and was then continuously stirred for 1 hr. r-Batroxobin solutions were 
prepared with concentrations of 1, 2, and 3 BU/well for in vitro and 3 and 5 
BU/well for in vivo experiments. Degassing was done to remove bubbles 
using a centrifuge at 3,000 rpm for 10 min at 4°C. Each solution was loaded 
on 24 well plate and frozen in a -78°C deep freezer for 48 hr. Finally, the 
frozen solution was lyophilized for 48 hr using a -50°C freeze-dryer 
(Daeiltech, Korea). All the samples were stored at 4°C before experiment use. 
13 
 
3. Characterization of the hemostatic pad  
Each sample was fixed with 2 % Glutaraldehyde-Paraformaldehyde in 0.1 
M PBS, pH 7.4, for 2 hr and washed three times for 30 min (90 min total) in 
0.1 M PBS. Each was post-fixed with 1 % Osmium Tetroxide (OsO4) 
dissolved in 0.1 M PBS for 2 hr and dehydrated in ascending gradual series 
(50–100 %) of ethanol and infiltrated with the Iso amyl acetate and subjected 
to Critical Point Dryer (HCP-2, Hitachi, Tokyo, Japan). They were coated 
with gold by ion sputter (IB-3, Eiko, kobe, Japan) 6 mA for 6 min and 
morphology of hemostatic pads were examined and photographed using Field 
Emission Scanning Electron Microscopy (FE SEM S-800, Hitachi, Tokyo, 
Japan) at an acceleration emission voltage of 20 kV. The average pore sizes 
of pads were determined from measurements on a typical FE SEM image. 
 
4. In vitro studies 
 
A. Fibrinogen clotting assay 
Firstly, 20 mM Trisma base prepared by dissolved in distilled water with 
a pH of 7.5 and dissolved fibrinogen solution of 10 mg/ml in 0.9 % warm 
saline. To execute fibrinogen conversion to fibrin by batroxobin released from 
the hemostatic pad, 400 μL of 20 mM Tris-HCl, pH 7.5, was added to the 
hemostatic pads containing r-Batroxobin 1, 2 and 3 BU/well and incubated for 
10 min at 37°C. After incubation, the buffer solution releasing batroxobin was 
collected. The buffer solution mixed with 10 mg/ml fibrinogen solution and 
incubated at 37°C for 10 min. Respective concentrations of r-Batroxobin 
reacted with fibrinogen and fibrin formation were confirmed by turbidity of 
the released solutions. The turbidity was detected at 405 nm by automatic 
microplate spectrophotometer. 
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B. Platelet activation assay 
Sprague-Dawley (SD) rat, weight 350–400 g, blood was collected using 
a syringe containing 0.109 M sodium citrate in a ratio of 4:1. To isolate high 
concentrations of platelet solution, whole blood was centrifuged at 2,500 rpm 
for 5 min, and platelet rich plasma (PRP) was separated from the red blood 
cell and further centrifuged at 2,500 rpm for 5 min to obtained pellets of rich 
platelets. The pellet was diluted with PBS in a 1:4 ratio and was added each 
hemostatic pad, r-Batroxobin 0, 1, 2 and 3 BU/well. After incubation at 37°C 
for 20 min, each hemostatic pad were removed and fixed with 2 % 
Glutaraldehyde-Paraformaldehyde in 0.1 M PBS, pH 7.4. Activated platelets 
were observed under FE SEM.  
 
C. Whole blood clotting assay 
Whole blood was obtained from male SD rats, weight 350–400 g, from 
the abdominal vena cava using a syringe containing 0.109 M sodium citrate in 
the ratio of 4:1. For anesthetic, 30 mg/kg Zoletil (Boehringer Ingelheim 
Agrovet, Hellerup, Denmark) and 10 mg/kg Rompun (Bayer, Toronto, 
Canada) were administered by intramuscular injection. The abdominal vena 
cava of the rats were exposed to collect the whole blood using a syringe 
containing 0.109 M sodium citrate in the ratio of 4:1. Each hemostatic pad, 
with various concentrations of r-Batroxobin in 0, 1, 2 and 3 BU/well were 
dipped in 24 well plates containing 400 μL of citrated blood, and then the 
plate was incubated with shaking at 37°C for 10 min. After incubation, 
unstable blood clots were dissolved by addition to PBS. The diluted blood in 
the PBS reacted with Drabkin’s solution in a 1:10 ratio and then gently 
rinsing 3 times with reagent by pipette. The solutions were mixed well and 
allowed to stand for 15 min at room temperature. The total hemoglobin 
concentration (mg/ml) of each hemostatic pad was determined at 540 nm 
using a Versamax (Molecular devices korea, Okchun, Korea). 
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5. In vivo studies 
 
A. Preparation of animal experiments 
 
(A) Animals 
All animal experiments were performed with the “Guide for the Care 
and Use of Laboratory Animals” and protocol approved by the Institutional 
Animal Care and Use Committee (IACUC) of the Yonsei Laboratory 
Animal Research Center (YLARC) (Permit #: 2015-0052). Animals were 
maintained in the specific pathogen-free facility of the YLARC. SD rats 
were used for in vivo studies. For the femoral artery model, 120 healthy 
male SD rats, weight 350–400 g, were randomly assigned to experiment 
groups. The liver model was randomly utilized with 120 healthy male SD 
rats, weight 230–280 g. Prior to in vivo studies, Zoletil and Rompun (as 
described above) were administered by intramuscular injection for 
anesthetic in in vitro studies.  
 
(B) Treatments 
Ten groups assigned to in vivo studies, including no treatment, only 
application of the collagen, chitosan, collagen with chitosan pads and each 
pad with concentrations of recombinant batroxobin (r-Batroxobin) of 3, 5 
BU/well. 
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B. Blood coagulation in SD rat model 
 
(A) Femoral artery model 
Amount of bleeding pattern and hemostasis time was evaluated by 
femoral artery model as described by You KE et al
30
 with a slight 
modification. Figure 4 images simplify shown that the process of femoral 
artery experiment. The anesthetized SD rat was fixed on a Styrofoam board 
using needles and tilted at about 45 degrees. The left leg was incised and 
muscle fascia removed to expose the femoral artery, and then the vessel 
was cut using a scalpel. After inflicting the injury, the treatments were 
applied (as per group) on the arterial wound area. After the application of 
the pad, filter paper was placed immediately below to absorb the blood. 
The filter paper was changed every 10 sec, and wet filter paper weight 
taken to determine total amount of bleeding and accurate times of cessation 
of bleeding. The experiment for each animal was defined as acute 
hemostasis bleeding stopped before 15 min. 
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Figure 4. Procedure of the femoral artery model of SD rat. (A) The left femoral 
artery was exposed and tilted a Styrofoam at about 45 degrees. (B) Femoral 
artery cut by using a scalpel. (C) Hemostatic pad directly applied on injury and 
placed filter paper below wound site. (D) Filter paper absorbed blood and 
replaced every 10 sec. (E) Acute hemostasis time point measured by unwetted 
paper. (F) Bleeding pattern confirmed to each treatment groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
(B) Liver model  
Prior to the experiments, the anesthetized SD rat was fixed on a 
Styrofoam board using needles and tilted at about 45 degrees. Figure 5 
explained liver model, briefly. After abdominal incision, the left lateral 
lobe of liver was exposed to make a hole. Then, the 5 x 5 cm
2
 para-film 
was placed under the liver lobe to prevent absorption of blood other than 
that from the wound site. The wound was made in the middle of lobe using 
a 4 mm biopsy punch and then free bleeding was allowed for 5 sec. While 
bleeding was profuse, a hemostatic pad applied on the left liver lobe and 
filter paper was placed below the liver. The filter paper was replaced every 
30 sec and immediately wet filter paper weight measured immediately to 
determine total amount of bleeding and accurate times of cessation of 
bleeding. The experiment for each animal was defined as acute hemostasis 
bleeding stopped before 5 min. 
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Figure 5. procedure of the liver injury model of SD rat. (A) The left lateral lobe 
of liver exposed to make a hole and placed parafilm and filter paper under the 
lobe. (B) A hole made by 4 mm biopsy punch and allowed free bleeding. (C) 
Hemostatic pad applied on the liver lobe. (D) Filter paper absorbed blood and 
changed every 30 sec. (E) Acute hemostasis time point measured and confirmed 
to maintenance of hemostasis for 1 min. (F) Bleeding pattern evaluated each 
hemostatic pad. 
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6. Histological analysis 
To examine the blood clot formation during in vivo studies, the liver lobe 
was isolated with wound tissue containing hemostatic pad. The isolated tissue 
was fixed in 10 % neutral buffered formaldehyde, dehydrated in grading 
ethanol, and embedded in paraffin. The paraffin block was vertically serially 
sectioned at 5 µm thickness, and then the tissue of the middle of wound site 
was found with a hole. The tissue produced were placed on slides glass, 
which were then de-paraffinized in an oven set at 60°C and stained with 
hematoxylin and eosin (H&E) for microscopic examination of blood clot 
formation. For fibrin clot formation, the tissue slides were de-paraffinized in 
an oven set at 60°C and stained with phosphotungstic acid hematoxylin 
(PTAH). PTAH stain visualized not only fibrin but also muscle dyed blue or 
bluish purple. 
 
7. Statistical analysis 
All results were statistically analyzed by Student t-test using Microsoft 
Office Excel 2010. Data are expressed as mean ± standard deviation of mean. 
P values <0.05 were considered statistically significant. 
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III. RESULTS 
 
1. Characteristics of hemostatic pad 
SEM images of the freeze-dried hemostatic pad are presented in Figure 6, 
indicating a micro-porous top layer. All groups had accurate 3D porous 
structure and relatively uniform pore-size distribution with inherent 
interconnectivity. Only collagen treated pad was determined to be 49.01±2.7 
μm, whereas collagen with r-Batroxobin groups were determined to be 
23.11±1.88 μm without reference to batroxobin concentration. That indicated 
the diameter of pore size increased after addition of r-Batroxobin to collagen. 
The chitosan groups showed less perfect shape of porous structure compared 
to collagen treated groups, but all chitosan treated groups had almost the 
same size as 55.19±2.69 μm. The collagen with chitosan containing 
r-Batroxobin groups were well interconnected with a mean pore size of 
57.79±6.65, 57.78±5.14, 55.96±5.91, 56.13±4.35 μm, respectively. The 
images were not changed structure even with concentration of r-Batroxobin 
treated.  
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Figure 6. SEM micrographs of the surface of the hemostatic pad on (A) Only 
collagen, (B) Collagen containing r-Batroxobin 1 BU/well, (C) Collagen 
containing r-Batroxobin 2 BU/well, (D) Collagen containing r-Batroxobin 3 
BU/well, (E) Only chitosan, (F) Chitosan containing r-Batroxobin 1 BU/well, 
(G) Chitosan containing r-Batroxobin 2 BU/well, (H) Chitosan containing 
r-Batroxobin 3 BU/well, (I) Collagen with chitosan, (J) Collagen with chitosan 
containing r-Batroxobin 1 BU/well, (K) Collagen with chitosan containing 
r-Batroxobin 2 BU/well, (L) Collagen with chitosan containing r-Batroxobin 3 
BU/well. Scale bar=50μm. 
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2. In vitro studies 
 
A. Fibrinogen clotting assay 
The turbidity of the solution was increased as shown in Figure 7. The 
more r-Batroxobin concentration was increased, the more fibrin 
polymerization increased compared with only collagen or chitosan pads. In 
the collagen treated groups, collagen with r-Batroxobin 2 BU/well was 
significantly increased in turbidity compared to the collagen-only pad, 
whereas chitosan groups showed no difference in turbidity with different 
concentrations of r-Batroxobin without chitosan-only treated pad. As the 
concentration of r-Batroxobin increased, the collagen with chitosan groups 
also increased fibrin turbidity. 
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Figure 7. Measurement of fibrin turbidity. Fibrinogen conversion to fibrin was 
formation by buffer solution containing r-Bat 1, 2 and 3 BU/well. The degree of 
fibrin formation was measured at 405nm using spectrometer. * P < 0.05 
compared to control(non-containing r-Batroxobin) treated group. 
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B. Platelet activation assay 
As Figure 8 shows, each hemostatic pad incubated with rich platelets 
were fixed and viewed under the SEM. Activated platelets were shown with 
pseudopod formation in all treated groups, but low numbers of activated 
platelets were observed in collagen or chitosan pads containing r-Batroxobin 
0, 1, 2 and 3 BU/well. In contrast, higher numbers of activated platelets were 
generated in collagen with chitosan pads containing r-Batroxobin 0, 1, 2 and 
3 BU/well, and significantly more platelet aggregation adhered onto the 
groups. 
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Figure 8. SEM images of the platelet activation of the hemostatic pad on (A) 
Only collagen, (B) Collagen containing r-Batroxobin 1 BU/well, (C) Collagen 
containing r-Batroxobin 2 BU/well, (D) Collagen containing r-Batroxobin 3 
BU/well, (E) Only chitosan, (F) Chitosan containing r-Batroxobin 1 BU/well, 
(G) Chitosan containing r-Batroxobin 2 BU/well, (H) Chitosan containing 
r-Batroxobin 3 BU/well, (I) Collagen with chitosan, (J) Collagen with chitosan 
containing r-Batroxobin 1 BU/well, (K) Collagen with chitosan containing 
r-Batroxobin 2 BU/well, (L) Collagen with chitosan containing r-Batroxobin 3 
BU/well. Scale bar=50μm. 
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C. Whole blood clotting assay 
For the investigation of blood clot formation in composite sponges, 
observation macroscopy use by photographic images and measurement of 
hemoglobin concentration in unformed clot blood. As the r-Batroxobin 
concentration was increased, clot formation was gradually elevated along 
with darkness of non-trapped clots, as shown in Figure 9. After measuring 
hemoglobin concentration, the degrees of clot formation was estimated with 
back calculation method and then converted into percentages. A higher 
absorbance degree of hemoglobin indicated slower formation rate.
11
 In figure 
10, about 50 % of clot formation was found in collagen- or chitosan-only 
treated groups compared to untreated group, and more clots were formed with 
the increasing concentrations of r-Batroxobin. With inclusion of 2 BU/well to 
hemostatic pad, the percentage of clot formation rapidly increased and an 
almost-completely formed clot was seen in the hemostatic pad containing 3 
BU/well. In addition, collagen with chitosan groups observed entirely formed 
clots by addition of 2 BU/well of r-Batroxobin as collagen or chitosan 
containing r-Batroxobin 3 BU/well. 
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Figure 9. Macroscopy of whole blood clot formation on hemostatic pad 
containing r-Batroxobin. Immediately incubated the scaffold with r-Batroxobin 
0, 1, 2 and 3 BU/well, clots take a photograph tilted at 30 degree. clots were 
expended through increasing concentrations of r-Batroxobin.  
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Figure 10. Whole blood clot formation on hemostatic pad containing 
r-Batroxobin. The degree of clot formation was represented to percentage of the 
control. Formed clotting was increased with r-Batroxobin and notably on the 
collagen or chitosan treated containing 3 BU/well r-Batroxobin and collagen 
with chitosan containing 2, 3 BU/well r-Batroxobin were completely formed 
than other treated groups. * P < 0.05 compared to control(non-containing 
r-Batroxobin) treated group. 
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3. In vivo studies 
 
A. Blood coagulation in femoral artery model 
The amount of blood loss was analyzed by measurement of the 
accumulated weight of blood absorbed by the filter paper, and accurate 
bleeding cessation time was recorded once filter papers absorbed no blood. In 
Figure 11, the graphs confirm the tendency of the hemostasis over 15 min, 
and the curves fitting on the bar indicate the pattern of hemostasis at each 
time point. Additionally, the total amount of bleeding out, first-bleeding, and 
re-bleeding were compared with each group calculated from the equation of 
the bleeding stop point in Figure 12 and Table 1. The reduction in blood 
bleeding out with time point is shown in Figure 11 but complete hemostasis 
was not achieved by 15 min, after which the injury remained untreated. In 
contrast, hemostatic pad was hemostasis time was sharply reduced compared 
with untreated group within 30 sec, even all treated groups were not equal. 
Moreover, increased r-Batroxobin concentration effectively lessened 
hemostasis time point and showed a remarkably reduced amount of 
re-bleeding out. Through Figure 12A, all treated groups blood loss amounts 
were small compared with the control (untreatment) group; also chitosan and 
collagen with chitosan containing 5 BU/well yielded more diminished 
amounts of blood. In the first-bleeding comparison graph in Figure 12B, all 
groups were similar in blood loss except the chitosan containing 5 BU/well. 
In addition, the amount of re-bleeding treatment containing r-Batroxobin 
groups were distinguished from those treated without r-Batroxobin. In fact, 
re-bleeding was almost non-existing when treated containing 5 BU/well, 
which reduced re-bleeding up to 0.1g compared with other groups in Figure 
12C. Table 1 shows the hemostasis time and generated re-bleeding time. With 
increased concentration of r-Batroxobin or collagen treated with chitosan, 
re-bleeding time was delayed and blood loss reduced. 
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Figure 11. Measurement of amount of blood from femoral artery injury model. 
The graphs observed tendency of the hemostasis with 15 min and the curves 
indicated the pattern of hemostasis each time point. (A) The untreated group.  
Bleeding could not stopped until 15 min. (B) Collagen-only, (C) Collagen 
containing r-Batroxobin 3 BU/well, (D) Collagen containing r-Batroxobin 5 
BU/well.  
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Figure 11. (continued) (E) Chitosan-only, (F) chitosan containing r-Batroxobin 
3 BU/well, (G) chitosan containing r-Batroxobin 5 BU/well.  
 
 
  
 
 
 
33 
 
 
Figure 11. (continued) (H) Collagen with chitosan, (I) Collagen with chitosan 
containing r-Batroxobin 3 BU/well, (J) Collagen with chitosan containing 
r-Batroxobin 5 BU/well. 
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Figure 12. Examination of (A) Total amount of blood from bleeding wound site, 
(B) First-bleeding and (C) Recurrence bleeding with hemostatic pad. All groups 
had blood loss which was oozed out again during hemostasis process, even 
though the scaffold completely covered the bleeding site. * P < 0.05 compared 
to untreated group. # P < 0.05 compared to non-containing r-Batroxobin treated 
group. 
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Table 1. Hemostasis time, recurrence bleeding time and total amount of blood 
bleeding out with various treatments in femoral artery model 
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B. Blood coagulation in liver model 
The hemostatic effects on the various treatment groups were examined by 
measurement of the accumulated weight of blood absorbed on filter paper and 
accurate bleeding cessation time. After punching a hole in the left liver lobe, 
were directly covered the wound site with a hemostatic pad to. According to 
Figure 13, the untreated group bleeding was not controlled within 5 min, but 
other treated groups with r-Batroxobin stopped bleeding within 3 min. The 
effect of hemostasis was significantly magnified when scaffold 5 BU/well of 
r-Batroxobin was included. By comparison with femoral artery model, liver 
model showed light bleeding site and no recurrence of bleeding. In addition, 
the gaps of total bleeding of groups were relatively slight between those 
treated with r-Batroxobin or not. However, blood loss was strikingly reduced 
in the r-Batroxobin 5 BU/well treated group compared with other treated 
groups. Figure 14 shows the total amount of bleeding out in the wound site. 
Prior to femoral artery experiments, when treated with escalated 
concentration of r-Batroxobin, blood loss in wound site was much reduced. 
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Figure 13. Measurement of amount of blood from liver wound model. The 
graphs observed tendency of the hemostasis with 5 min and the curves indicated 
the pattern of hemostasis each time point. (A) The untreated group. Bleeding 
could not stopped until 15 min. (B) Only collagen, (C) Collagen containing 
r-Batroxobin 3 BU/well, (D) Collagen containing r-Batroxobin 5 BU/well. 
 
 
38 
 
 
Figure 13. (continued) (E) Only chitosan, (F) chitosan containing r-Batroxobin 
3 BU/well, (G) chitosan containing r-Batroxobin 5 BU/well. 
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Figure 13. (continued) (H) Collagen with chitosan group, (I) Collagen with 
chitosan containing r-Batroxobin 3 BU/well, (J) Collagen with chitosan 
containing r-Batroxobin 5 BU/well. 
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Figure 14. Examination of total blood loss in liver bleeding wound site. The 
total amount of bleeding out significantly reduced in hemostatic pad containing 
recombinant batroxobin. * P < 0.05 compared to untreated group. # P < 0.05 
compared to non-containing r-Batroxobin treated group. 
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4. Histological analysis 
   Histological results of blood and fibrin clot formation were examined by 
both H&E staining and PTAH staining. H&E staining allowed visualization of 
blood clot formation via the use of erythrocyte dye and PTAH staining that 
was specific to fibrin. As Figure 15 shows, blood clots were stained pinkish 
red via H&E staining, which was observed in the wound hole of the liver lobe. 
Figures 15A, 15D and 15G were treated without r-Batroxobin. The images 
show low concentration of blood clot formation in the areas. In contrast, the 
more the hemostatic pad increased the r-Batroxobin concentration, the more 
blood clots formed and its intensity was significantly increased. The results 
were matched to blood density through by images from Figure 15a to Figure 
15i. The images that were treated with r-Batroxobin 5 BU/well include more 
high dense pinkish red dye than the r-Batroxobin 0 and 3 BU/well.   
   In another staining method, fibrin was stained bluish purple by PTAH 
staining. As represented in Figure 16, Figures 16A, 16D and 16G images 
show that fibrin clots were seldom found around the wound hole with bluish 
dye. Whereas hemostatic pad containing r-Batroxobin groups were observed 
with a relatively larger and deep bluish purple area. Especially Figure 16I 
included a high dense of stained area and dark purple dyed. Therefore, Figures 
15 and 16 support that more blood clots and fibrin clots were formed with an 
increased concentrated r-Batroxobin in the wound area. 
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Figure 15. Histological photomicrographs of the liver wound site with blood 
clot formation. The images were histologically examined by H&E staining. 
(A)-(I) images were taken at 40x magnification and (a)-(i) images were taken at 
100x magnification. Collagen treated group: (A)-(C); Chitosan treated group: 
(D)-(F); Collagen with Chitosan treated group: (G)-(I); (A), (D) and (G) natural 
substances with no r-Batroxobin; (B), (E) and (H) natural substances containing 
r-Batroxobin 3 BU/well; (C), (F) and (I) natural substances containing 
r-Batroxobin 5 BU/well. 40x magnification bar indicates 500 μm and 100x  
magnification bar indicates 200 μm. 
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Figure 16. Histological photomicrographs of liver wound site with fibrin clot 
formation. The images were histologically examined by PTAH staining. (A)-(I) 
images were taken at 40x magnification and (a)-(i) images were taken at 100x 
magnification. Collagen treated group: (A)-(C); Chitosan treated group: (D)-(F); 
Collagen with Chitosan treated group: (G)-(I); (A), (D) and (G) natural 
substances with no r-Batroxobin; (B), (E) and (H) natural substances containing 
r-Batroxobin 3 BU/well; (C), (F) and (I) natural substances containing 
r-Batroxobin 5 BU/well. 40x magnification bar indicates 500 μm and 100x  
magnification bar indicates 200 μm. 
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IV. DISCUSSION 
 
Complimentary balance of fibrinolytic pathway and complex interactions 
with composition in blood vessel is an essential prerequisite for successful 
hemostasis.
1
 Hence, difference mechanisms used are very important and give a 
more striking effect to blood coagulation in hemostasis. It is known that 
collagen and chitosan can promote platelet activation and aggregation in 
intrinsic pathway,
31
 also, chitosan induces the blood clot formation as combined 
with erythrocyte cell.
32
 Batroxobin accelerates conversion of fibrinogen to fibrin 
to help blood clot formation.
21
 
In this research, fabrication of the hemostatic pads composed of collagen 
with chitosan containing various concentrations of recombinant batroxobin was 
shown, and it demonstrated effects on rapid hemostasis through in vitro and in 
vivo studies.  
First, when collagen and chitosan fabricated pads with various r-Batroxobin 
concentrations were used, the sponges were confirmed any properties changes 
compared to collagen or chitosan only treated pads. The prepared hemostatic 
pad SEM images showed that the hemostatic pads of collagen and chitosan 
containing r-Batroxobin 0, 1, 2 and 3 BU/well did not affect micro structural 
characteristics with retention of the suitable pore size in Figure 6. The 
difference in pore size between collagen and chitosan was determined by the 
substances properties. Collagen can be more easily combined with substances 
other than chitosan powder, so blending with another natural material gives 
higher porosity in collagen treated groups.
33-36
 From the fibrinogen conversion 
fibrin experiment result, r-Batroxobin maintained their hemostatic mechanism 
even if mixed with natural substances. As the measurement of fibrin turbidity, 
r-Batroxobin treated with collagen and with collagen and chitosan groups 
showed higher turbidity than r-Batroxobin treated with chitosan groups. The 
reason for collagen-based materials can swell with tissue compression.
11
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Hemostatic pads including collagen had higher-porosity structure, so 
r-Batroxobin was easily released from the pad. In addition to platelet activation 
assay, the collagen and chitosan hemostatic mechanism also was not lost when 
combined with r-Batoxobin. That result was expected as collagen and chitosan 
used together for increase of coagulation effect. Chitosan binds and aggregates 
platelets, as well as agglutination of erythrocyte, and collagen affects platelet 
adhesion and subsequent activation in hemostatic mechanism.
1,19,20,37
 In Firgure 
8, SEM micrographs also show the precise spread of platelets with protruding 
pseudopods. In order to achieve the synergetic effect of respective hemostats 
mechanism, whole blood was kept with the hemostat pad groups. For 
comparison, a not treated group was used as control. The clot formation is 
shown in Figure 9, which shows that the group treated with r-Batroxobin 
3BU/well had much better blood clot ability compared with other groups. 
Moreover, collagen with chitosan containing r-Batroxobin 2 BU/well performed 
equally well in this respect. Chitosan-treated groups had higher percentages of 
clot than collagen-treated groups. As mentioned above, that was due to chitosan 
affecting not only platelet aggregation but also binding with red blood cell.
38,39
  
A previous study that achieved hemostasis by biodegradable adhesive with 
batroxobin in different animals,
30,40
 it has led to a set of animal experiments to 
determined that synergetic effect of fabricated hemostatic pad. The efficacy of 
r-Batroxobin reconfirmed the result of SD rat femoral artery model in Figures 
11 and Table 1. According to the result, all groups of hemostatic pad shortened 
bleeding time lag with increasing concentration of r-Batroxobin compared with 
collagen-only or chitosan-only treated groups. When the hemostatic pad did not 
cover bleeding in injury site completely, bleeding ooze occurred because the 
femoral artery is high blood flow site.
41
 However, with increased concentration 
of r-Batroxobin, recurrence bleeding in the wound site reduced. r-Batroxobin 
can play an important role of a second barrier for coagulation. During the 
process of hemostasis in the site, collagen and chitosan cooperated with 
46 
 
r-Batroxobin to rapidly control bleeding. In addition, SD rat puncture model 
result have been shown to stop bleeding rapidly in hepatic parenchymal as well 
as exclusive bleeding model. In other liver wound models, the wound was made 
by a prick.
42
 This experiment result concerned higher blood loss because the 
wound made by a hole in the liver lobe.
43
 The hemostats pad containing 
r-Batroxobin could be completely adhered on the surrounding hepatic tissue and 
rapidly solidified to assist the bleeding barrier within 30 sec. Figure 14 shows 
that the amount of total blood loss was conspicuously reduced in the group 
treated with r-Batroxobin 5 BU/well.  
Histological examination of the wound, which was covered with blood clots 
and fibrin clots, also showed that three substances generated synergetic effects 
and functionality of r-Batroxobin. In other studies that conformed to 
histological analysis without any treatment for the wound area, the blood from 
the bleeding flowed, so clots hardly formed.
9, 30
 As Figures 15A(a), 15D(d) and 
15G(g), the images show that only collagen or chitosan treated groups rarely 
exhibited clot formation and not be enough to present upon examination. By 
contrast, Figures 15B(b)-15I(i) formed blood clots with more dense stained 
pinkish red by the addition of r-Batroxobin 3 or 5 BU/well. Especially Figures 
15C(c), 15F(f) and 15I(i), containing r-Batroxobin 5 BU/well, were definitely 
deep stained blood clot with high density. The results clearly support that the 
synergetic effect of respective substances at the hemorrhage site. Moreover the 
fibrin was selectively stained by PTAH staining method because only H&E 
staining result was not sufficiently complete for efficacy of r-Batroxobin. Thus, 
the fibrin formation promoted the entrapped dye with erythrocyte.
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 As H&E 
images with r-Batroxobin, PTAH staining results also with r-Batroxobin 
provided an excellent environment for advanced fibrin clots. Furthermore 
Figures 16H(h) and 16I(i) fully show deep clots formation. As the entrapped 
erythrocytes were stained with fibrin, the increase in the amount of blood clots 
might be more highly distinguished through the PTAH staining. This was 
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already confirmed in the quantitative analysis of the liver wound model. The 
amount of blood loss was decreased with the treatment of r-Batroxobin.  
Overall experimental results support the hypothesis that collagen, chitosan 
and batroxobin have a synergetic effect on treating an injury site. In addition  
batroxobin reacted to enhance the hemostatic function of the natural substances 
pad. r-Batroxobin revealed an excellent hemostatic ability in conjunction with 
collagen and chitosan at the bleeding site. They also confirmed that early stage 
hemostasis was accelerated by increasing of r-Batroxobin concentration in an 
animal model.  
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V. CONCLUSION 
 
Collagen and chitosan hemostatic pads exhibited analogous hemostatic 
efficacy and hemostasis success rate in experiments. Furthermore, r-Batroxobin 
was reconfirmed as having excellent hemostatic properties and offering a stable 
barrier in excessive bleeding. This is first utility evaluation of collagen and 
chitosan containing r-Batroxobin for internal clinical use. Based on the result 
shown above, a novel hemostatic pad has great potential for uncontrolled 
bleeding injury treatment.  
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ABSTRACT(IN KOREAN) 
 
배트록소빈 함유에 의한  
콜라겐과 키토산 지혈패드의 기능적 효과 
 
<지도교수  박 종 철> 
 
연세대학교 대학원 의과학과 
 
선 경 미 
 
 
일상생활에서나 갑작스러운 사고, 수술과정 또는 전쟁 중 
제어할 수 없는 과도한 출혈은 감염성 합병증을 초래하여 
쇼크에 의해 사망에 이를 수 있게 한다. 그러므로 최종적인 
치료 전 급성 출혈을 효과적으로 도우며 환자를 안정에 이르게 
하기 위하여 국소 지혈제와 밀폐제를 필요로 하게 된다. 이번 
연구에서는 오늘날 지혈제로서 널리 이용되고 있는 천연물질인 
콜라겐과 키토산을 사용하였는데, 두 물질은 지혈에서 혈소판의 
활성과 응집의 역할을 하게 된다. 또한 키토산은 적혈구와의 
결합으로 혈액 응고를 돕기도 한다. 그러나 이 물질들만으로는 
적절한 시간 내에 지혈효과를 내기에 충분하지 않다는 많은 
연구 결과들이 보고되어져 왔다.  
이러한 이유로 본 연구에서는 지혈과정에서 피브리노겐을 
피브린으로 전환하여 출혈을 제어하는 기능의 물질로 Bothrops 
atrox moojeni 라는 뱀의 독성 성분 일종인 배트록소빈을 
이용하여 더욱 빠르고 효과적인 스펀지 타입의 새로운 지혈제를 
만들었으며, 이를 통해 사용된 재조합 배트록소빈이 지혈 
기능의 측면에서 천연물질 성분에 시너지 효과를 줄 수 있을 
것이라고 기대하였다. 먼저 콜라겐과 키토산을 재조합 
배트록소빈과 함께 아세트산에 녹여 새로운 지혈패드를 
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제작하였고 그의 표면적 특성을 주사전자현미경법을 통해 비교, 
확인 하였다. 제작된 스펀지는 콜라겐, 키토산, 콜라겐과 키토산,  
in vitro 실험을 위한 콜라겐 또는 키토산에 재조합 배트록소빈 
(1, 2, 3 BU/well)이 포함된 군, in vivo 실험을 위한 콜라겐 또는 
키토산에 재조합 배트록소빈 (3, 5 BU/well)이 포함된 군, 
콜라겐과 키토산에 재조합 배트록소빈(1, 2, 3, 5 BU/well)이 
포함된 군으로 나누어 진행하였다. 피브리노겐 응고 분석과 
혈소판 활성 분석을 통해 물질들이 혼합되어 있음에도 각각의 
지혈 기전을 유지하고 있는지를 확인하였으며, 전혈 응고 
분석과 동물실험을 통해서 부상 위치에서 혈액 응고 활성을 
보이는 지를 조사하였다. 또한,  H&E와 PTAH 염색 방법을 
통해 생성된 혈전 생성과 피브린 응집 정도를 조직학적 분석을 
통해 확인 하였다. 위와 같은 실험들의 결과를 통해, 새로운 
지혈패드가 패드 안에서 각각의 지혈 효과를 유지하고 있음을 
확인하고 혈액 응고 실험들을 통해 재조합 배트록소빈의 함유를 
통해 출혈시간과 출혈량을 효과적으로 줄인다는 것을 
입증하였다. 
결론적으로, 본 연구를 통해 제작된 새로운 지혈패드는 과다 
출혈 부상에 적용하기에 엄청난 가능성을 가지고 있으며 재조합 
배트록소빈과 더해졌을 때 그 천연물질에 효과가 더해졌음을 
입증하였다. 
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